MILabs, B.V. the Netherlands‐based innovator and manufacturer of pre‐clinical SPECT/PET/CT imaging devices announces the release of the Plus! Systems: the U‐SPECT+ and U‐SPECT+ /CT.
Both systems achieve for the first time reconstructed SPECT resolution of ¼mm utilizing a new, super high‐resolution collimator design. Significant resolution improvements (up to 15%) were also realized for the existing U‐SPECT multi‐pinhole collimator family that is based on MILabs
TM proprietary M5 dual‐stage technology. Resolution gains were validated using Jaszczak phantom measurements while superior in vivo results are currently demonstrated by investigators in cardiac, neuroscience, oncology and pharmaceutical research, which will open new frontiers in
Additionally, MILabs introduces ultra‐high‐sensitive SPECT capability of >12,000 cps/MBq. This enables extremely low‐dose experiments and accurate analysis of very fast tracer dynamics. MILabs now also offers new imaging beds and cells optimized for obesity studies.
Also with these Plus! systems, MILabs announces dynamic sub‐half‐minute whole‐body mouse SPECT. This novel technique is accomplished with the benefit of the MILabs highly stable stationary detector design which is heralded by many researchers involved in e.g. pharmacokinetic
Extending the U‐SPECT/CT and VECTor/CT hybrid SPECT/PET modality functionality, MILabs announces with the Plus! the integration of data from most high‐performance MRI platforms.